JAK3/BTK-IN-4

JAK3/BTK-IN-4

• CAS Number: 2673196-38-6
• UNSPSC Description: JAK3/BTK-IN-4 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-4 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147953A1, compound 003)[1]
• Target Antigen: Btk; JAK
• Type: Reference compound
• Related Pathways: Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt
• Applications: COVID-19-immunoregulation
• Field of Research: Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/jak3-btk-in-4.html
• Solubility: 10 mM in DMSO
• Smiles: C=CC(N(CCC1)CC21CCN2C3=C4C(NC=C4Cl)=NC(NC5=CN(CC)N=C5)=N3)=O
• Molecular Weight: 440.93
• References & Citations: [1]Baoguo Zhang, et al. Pyrimidinopyrimidine and pentacyclic derivatives and their applications. Patent WO2021147953A1.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported